Export 20 results:
Author Title Type [ Year(Asc)]
Filters: Author is Koup, Richard A  [Clear All Filters]
2017
J. E. Ledgerwood, DeZure, A. D., Stanley, D. A., Coates, E. E., Novik, L., Enama, M. E., Berkowitz, N. M., Hu, Z., Joshi, G., Ploquin, A., Sitar, S., Gordon, I. J., Plummer, S. A., Holman, L. S. A., Hendel, C. S., Yamshchikov, G., Roman, F., Nicosia, A., Colloca, S., Cortese, R., Bailer, R. T., Schwartz, R. M., Roederer, M., Mascola, J. R., Koup, R. A., Sullivan, N. J., and Graham, B. S., “Chimpanzee Adenovirus Vector Ebola Vaccine.”, N Engl J Med, vol. 376, no. 10, pp. 928-938, 2017.
2016
M. D. Tapia, Sow, S. O., Lyke, K. E., Haidara, F. Cheick, Diallo, F., Doumbia, M., Traore, A., Coulibaly, F., Kodio, M., Onwuchekwa, U., Sztein, M. B., Wahid, R., Campbell, J. D., Kieny, M. - P., Moorthy, V., Imoukhuede, E. B., Rampling, T., Roman, F., De Ryck, I., Bellamy, A. R., Dally, L., Mbaya, O. Tshiani, Ploquin, A., Zhou, Y., Stanley, D. A., Bailer, R., Koup, R. A., Roederer, M., Ledgerwood, J., Hill, A. V. S., W Ballou, R., Sullivan, N., Graham, B., and Levine, M. M., “Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-bli”, Lancet Infect Dis, vol. 16, no. 1, pp. 31-42, 2016.
2015
M. C. Crank, Gordon, I. J., Yamshchikov, G. V., Sitar, S., Hu, Z., Enama, M. E., Holman, L. S. A., Bailer, R. T., Pearce, M. B., Koup, R. A., Mascola, J. R., Nabel, G. J., Tumpey, T. M., Schwartz, R. M., Graham, B. S., and Ledgerwood, J. E., “Phase 1 study of pandemic H1 DNA vaccine in healthy adults.”, PLoS One, vol. 10, no. 4, p. e0123969, 2015.
U. N. Sarwar, Costner, P., Enama, M. E., Berkowitz, N., Hu, Z., Hendel, C. S., Sitar, S., Plummer, S., Mulangu, S., Bailer, R. T., Koup, R. A., Mascola, J. R., Nabel, G. J., Sullivan, N. J., Graham, B. S., and Ledgerwood, J. E., “Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial.”, J Infect Dis, vol. 211, no. 4, pp. 549-57, 2015.
H. Kibuuka, Berkowitz, N. M., Millard, M., Enama, M. E., Tindikahwa, A., Sekiziyivu, A. B., Costner, P., Sitar, S., Glover, D., Hu, Z., Joshi, G., Stanley, D., Kunchai, M., Eller, L. Anne, Bailer, R. T., Koup, R. A., Nabel, G. J., Mascola, J. R., Sullivan, N. J., Graham, B. S., Roederer, M., Michael, N. L., Robb, M. L., and Ledgerwood, J. E., “Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.”, Lancet, vol. 385, no. 9977, pp. 1545-54, 2015.
2014
U. N. Sarwar, Novik, L., Enama, M. E., Plummer, S. A., Koup, R. A., Nason, M. C., Bailer, R. T., McDermott, A. B., Roederer, M., Mascola, J. R., Ledgerwood, J. E., and Graham, B. S., “Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial.”, PLoS One, vol. 9, no. 9, p. e106240, 2014.
M. E. Enama, Ledgerwood, J. E., Novik, L., Nason, M. C., Gordon, I. J., Holman, L. S., Bailer, R. T., Roederer, M., Koup, R. A., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).”, PLoS One, vol. 9, no. 3, p. e91366, 2014.
L. - J. Chang, Dowd, K. A., Mendoza, F. H., Saunders, J. G., Sitar, S., Plummer, S. H., Yamshchikov, G., Sarwar, U. N., Hu, Z., Enama, M. E., Bailer, R. T., Koup, R. A., Schwartz, R. M., Akahata, W., Nabel, G. J., Mascola, J. R., Pierson, T. C., Graham, B. S., and Ledgerwood, J. E., “Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.”, Lancet, vol. 384, no. 9959, pp. 2046-52, 2014.
2013
B. S. Graham, Enama, M. E., Nason, M. C., Gordon, I. J., Peel, S. A., Ledgerwood, J. E., Plummer, S. A., Mascola, J. R., Bailer, R. T., Roederer, M., Koup, R. A., and Nabel, G. J., “DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.”, PLoS One, vol. 8, no. 4, p. e59340, 2013.
J. E. Ledgerwood, Zephir, K., Hu, Z., Wei, C. - J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect.”, J Infect Dis, vol. 208, no. 3, pp. 418-22, 2013.
J. P. Casazza, Bowman, K. A., Adzaku, S., Smith, E. C., Enama, M. E., Bailer, R. T., Price, D. A., Gostick, E., Gordon, I. J., Ambrozak, D. R., Nason, M. C., Roederer, M., Andrews, C. A., Maldarelli, F. M., Wiegand, A., Kearney, M. F., Persaud, D., Ziemniak, C., Gottardo, R., Ledgerwood, J. E., Graham, B. S., and Koup, R. A., “Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.”, J Infect Dis, vol. 207, no. 12, pp. 1829-40, 2013.
2011
J. E. Ledgerwood, Wei, C. - J., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., Bailer, R., Tumpey, T. M., Koup, R. A., Mascola, J. R., Nabel, G. J., and Graham, B. S., “DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials.”, Lancet Infect Dis, vol. 11, no. 12, pp. 916-24, 2011.
J. E. Ledgerwood, Pierson, T. C., Hubka, S. A., Desai, N., Rucker, S., Gordon, I. J., Enama, M. E., Nelson, S., Nason, M., Gu, W., Bundrant, N., Koup, R. A., Bailer, R. T., Mascola, J. R., Nabel, G. J., and Graham, B. S., “A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.”, J Infect Dis, vol. 203, no. 10, pp. 1396-404, 2011.
2010
R. A. Koup, Roederer, M., Lamoreaux, L., Fischer, J., Novik, L., Nason, M. C., Larkin, B. D., Enama, M. E., Ledgerwood, J. E., Bailer, R. T., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.”, PLoS One, vol. 5, no. 2, p. e9015, 2010.
W. Jaoko, Karita, E., Kayitenkore, K., Omosa-Manyonyi, G., Allen, S., Than, S., Adams, E. M., Graham, B. S., Koup, R. A., Bailer, R. T., Smith, C., Dally, L., Farah, B., Anzala, O., Muvunyi, C. M., Bizimana, J., Tarragona-Fiol, T., Bergin, P. J., Hayes, P., Ho, M., Loughran, K., Komaroff, W., Stevens, G., Thomson, H., Boaz, M. J., Cox, J. H., Schmidt, C., Gilmour, J., Nabel, G. J., Fast, P., and Bwayo, J., “Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.”, PLoS One, vol. 5, no. 9, p. e12873, 2010.
2008
J. E. Martin, Louder, M. K., Holman, L. S. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., Bailer, R. T., Gomez, P. L., Nason, M., Mascola, J. R., Nabel, G. J., and Graham, B. S., “A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.”, Vaccine, vol. 26, no. 50, pp. 6338-43, 2008.
2007
A. T. Catanzaro, Roederer, M., Koup, R. A., Bailer, R. T., Enama, M. E., Nason, M. C., Martin, J. E., Rucker, S., Andrews, C. A., Gomez, P. L., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.”, Vaccine, vol. 25, no. 20, pp. 4085-92, 2007.
J. Parrino, McCurdy, L. H., Larkin, B. D., Gordon, I. J., Rucker, S. E., Enama, M. E., Koup, R. A., Roederer, M., Bailer, R. T., Moodie, Z., Gu, L., Yan, L., and Graham, B. S., “Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.”, Vaccine, vol. 25, no. 8, pp. 1513-25, 2007.
2006
A. T. Catanzaro, Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., Butman, B. T., Gall, J. G. D., C King, R., Andrews, C. A., Sheets, R., Gomez, P. L., Mascola, J. R., Nabel, G. J., and Graham, B. S., “Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.”, J Infect Dis, vol. 194, no. 12, pp. 1638-49, 2006.
B. S. Graham, Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Martin, J. E., McCluskey, M. M., Chakrabarti, B. K., Lamoreaux, L., Andrews, C. A., Gomez, P. L., Mascola, J. R., and Nabel, G. J., “Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.”, J Infect Dis, vol. 194, no. 12, pp. 1650-60, 2006.